Home LiteratureArticle Details
PMID: 10510327 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells.

The Journal of clinical investigation ·Vol. 104 ·No. 7 ·1999-10-00 ·Pages 865-74

Baldassarre G, Belletti B, Bruni P, Boccia A, Trapasso F, Pentimalli F, Barone MV, Chiappetta G, Vento MT, Spiezia S, Fusco A, Viglietto G

Abstract

The majority of thyroid carcinomas maintain the expression of the cell growth suppressor p27, an inhibitor of cyclin-dependent kinase-2 (Cdk2). However, we find that 80% of p27-expressing tumors show an uncommon cytoplasmic localization of p27 protein, associated with high Cdk2 activity. To reproduce such a situation, a mutant p27 devoid of its COOH-terminal nuclear-localization signal was generated (p27-NLS). p27-NLS accumulates in the cytoplasm and fails to induce growth arrest in 2 different cell lines, indicating that cytoplasm-residing p27 is inactive as a growth inhibitor, presumably because it does not interact with nuclear Cdk2. Overexpression of cyclin D3 may account in part for p27 cytoplasmic localization. In thyroid tumors and cell lines, cyclin D3 expression was associated with cytoplasmic localization of p27. Moreover, expression of cyclin D3 in thyroid carcinoma cells induced cytoplasmic retention of cotransfected p27 and rescued p27-imposed growth arrest. Endogenous p27 also localized prevalently to the cytoplasm in normal thyrocytes engineered to stably overexpress cyclin D3 (PC-D3 cells). In these cells, cyclin D3 induced the formation of cytoplasmic p27-cyclin D3-Cdk complexes, which titrated p27 away from intranuclear complexes that contain cyclins A-E and Cdk2. Our results demonstrate a novel mechanism that may contribute to overcoming the p27 inhibitory threshold in transformed thyroid cells.

MeSH Terms
CDC2-CDC28 Kinases Cell Cycle Proteins Cell Nucleus/metabolism Cyclin D3 Cyclin-Dependent Kinase 2 Cyclin-Dependent Kinase Inhibitor p27 Cyclin-Dependent Kinases/antagonists & inhibitors,metabolism Cyclins/genetics,metabolism Cytoplasm/metabolism Genes, Tumor Suppressor Humans Microtubule-Associated Proteins/genetics,metabolism Protein Serine-Threonine Kinases/metabolism Signal Transduction Substrate Specificity Thyroid Neoplasms/metabolism,pathology Tumor Cells, Cultured Tumor Suppressor Proteins
Chemicals
CCND3 protein, human Cell Cycle Proteins Cyclin D3 Cyclins Microtubule-Associated Proteins Tumor Suppressor Proteins Cyclin-Dependent Kinase Inhibitor p27 Protein Serine-Threonine Kinases CDC2-CDC28 Kinases CDK2 protein, human Cyclin-Dependent Kinase 2 Cyclin-Dependent Kinases
Authors & Affiliations
12 authors, click to expand affiliations / ORCID
Baldassarre G
Istituto Nazionale dei Tumori "Fondazione Senatore Pascale," 80131 Naples, Italy.
Belletti B
Bruni P
Boccia A
Trapasso F
Pentimalli F
Barone M V
Chiappetta G
Vento M T
Spiezia S
Fusco A
Viglietto G
References (36)
36 references, click to expand
  1. Key role of the cyclin-dependent kinase inhibitor p27kip1 for embryonal carcinoma cell survival and differentiation.
    Oncogene. 1999 Nov 4;18(46):6241-51 PMID: 10597222
  2. Subcellular and cell-cycle expression profiles of CDK-inhibitors in normal differentiating myeloid cells.
    Blood. 1999 May 1;93(9):2907-17 PMID: 10216085
  3. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas.
    Cell. 1990 Feb 23;60(4):557-63 PMID: 2406025
  4. A genetic model for colorectal tumorigenesis.
    Cell. 1990 Jun 1;61(5):759-67 PMID: 2188735
  5. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis.
    Mol Endocrinol. 1990 Oct;4(10):1474-9 PMID: 2283998
  6. Cloning and characterization of human cyclin D3, a cDNA closely related in sequence to the PRAD1/cyclin D1 proto-oncogene.
    J Biol Chem. 1992 Oct 5;267(28):20412-5 PMID: 1383201
  7. Molecular basis of epithelial tumorigenesis: the thyroid model.
    Crit Rev Oncog. 1993;4(1):1-23 PMID: 8416149
  8. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.
    J Clin Invest. 1993 Jan;91(1):179-84 PMID: 8423216
  9. Regulation of the cell cycle by the cdk2 protein kinase in cultured human fibroblasts.
    J Cell Biol. 1993 Apr;121(1):101-11 PMID: 8458862
  10. Mammalian G1 cyclins.
    Cell. 1993 Jun 18;73(6):1059-65 PMID: 8513492
  11. WAF1, a potential mediator of p53 tumor suppression.
    Cell. 1993 Nov 19;75(4):817-25 PMID: 8242752
  12. Distinct roles for cyclin-dependent kinases in cell cycle control.
    Science. 1993 Dec 24;262(5142):2050-4 PMID: 8266103
  13. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals.
    Cell. 1994 Jul 15;78(1):59-66 PMID: 8033212
  14. The differential localization of human cyclins A and B is due to a cytoplasmic retention signal in cyclin B.
    EMBO J. 1994 Aug 15;13(16):3772-81 PMID: 8070405
  15. G1 phase progression: cycling on cue.
    Cell. 1994 Nov 18;79(4):551-5 PMID: 7954821
  16. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution.
    Genes Dev. 1995 Mar 15;9(6):639-49 PMID: 7729683
  17. The retinoblastoma protein and cell cycle control.
    Cell. 1995 May 5;81(3):323-30 PMID: 7736585
  18. Inhibitors of mammalian G1 cyclin-dependent kinases.
    Genes Dev. 1995 May 15;9(10):1149-63 PMID: 7758941
  19. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors.
    Cell. 1996 May 31;85(5):707-20 PMID: 8646779
  20. Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc.
    EMBO J. 1996 Dec 2;15(23):6595-604 PMID: 8978686
  21. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer.
    Nat Med. 1997 Feb;3(2):227-30 PMID: 9018244
  22. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas.
    Nat Med. 1997 Feb;3(2):231-4 PMID: 9018245
  23. The subcellular locations of p15(Ink4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2.
    Genes Dev. 1997 Feb 15;11(4):492-503 PMID: 9042862
  24. New functional activities for the p21 family of CDK inhibitors.
    Genes Dev. 1997 Apr 1;11(7):847-62 PMID: 9106657
  25. Cyclin E-CDK2 is a regulator of p27Kip1.
    Genes Dev. 1997 Jun 1;11(11):1464-78 PMID: 9192873
  26. A cytoplasmic inhibitor of the JNK signal transduction pathway.
    Science. 1997 Aug 1;277(5326):693-6 PMID: 9235893
  27. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer.
    Cancer Res. 1997 Aug 15;57(16):3381-5 PMID: 9270000
  28. Biological activity of p27kip1 and its amino- and carboxy-terminal domains in G2/M transition of Xenopus oocytes.
    Oncogene. 1997 Nov 20;15(21):2541-51 PMID: 9399642
  29. Localization and expression of p27KIP1 in multistage colorectal carcinogenesis.
    Cancer Res. 1998 Jan 1;58(1):114-22 PMID: 9426067
  30. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors.
    Mod Pathol. 1998 Feb;11(2):169-74 PMID: 9504687
  31. A requirement for cyclin D3-cyclin-dependent kinase (cdk)-4 assembly in the cyclic adenosine monophosphate-dependent proliferation of thyrocytes.
    J Cell Biol. 1998 Mar 23;140(6):1427-39 PMID: 9508775
  32. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma.
    Cancer Res. 1998 Apr 15;58(8):1730-5 PMID: 9563491
  33. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells.
    Oncogene. 1998 May;16(20):2575-83 PMID: 9632134
  34. Increase in AP-1 activity is a general event in thyroid cell transformation in vitro and in vivo.
    Oncogene. 1998 Jul 23;17(3):377-85 PMID: 9690519
  35. Immunohistochemical analysis of p27/kip1 expression in thyroid carcinoma.
    Mod Pathol. 1998 Aug;11(8):735-9 PMID: 9720501
  36. The WHO histological classification of thyroid tumors: a commentary on the second edition.
    Cancer. 1989 Mar 1;63(5):908-11 PMID: 2914297
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
Published
1999-10-00
Pages
865-74
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC408550
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]